Back to Market返回行情

CCM Concord Medical Services Holdings Limited

USHealthcare
$5.03+2.97%ClosedMarket Cap: $731,710

As of 2026-07-10 15:53

Why CCM matters now

Concord Medical Services Holdings Limited (CCM) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.03 with +2.97% on the session and $731.7K in market capitalization; recent performance reads 1-month +7.69% and YTD +37.82%.

The latest financial table shown here is Q4 2025, with revenue of $255.1M, net income of $-64.5M, and EPS of $-444.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.0%.

The latest indexable market news headline is "TWO Urges Stockholders to Vote FOR the CCM Transaction Today; Failure to Approve Risks a Significant Decline in TWO's Stock Price" from Business Wire.

Additional event context on this page matters because analyst consensus is Sell with a median target of $—; recent insider activity includes Zhang Liping filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

-0.00

P/S

0.01

EV/EBITDA

-13.87

DCF Value

$2,263,209.84

FCF Yield

0.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

1.2%

Operating Margin

-75.2%

Net Margin

-29.6%

ROE

7.2%

ROA

-2.4%

ROIC

-7.2%

Financials

PeriodRevenueNet IncomeEPS
Q4 2025$255.1M$-64.5M$-444.60
FY 2025$460.5M$-92.8M$-621.00
Q2 2025$100.3M$-13.6M$-94.50
Q1 2025$100.3M$-13.6M$-94.50

Analyst Ratings

Consensus

Sell

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 0Hold: 0Sell: 1Strong Sell: 0

Trading Activity

Insider Trades

Zhang Lipingdirector
Sell2026-03-18
Liu Hongzhongdirector:
Sell2026-03-18
Jiang Wei (NMN)officer
Sell2026-03-18
Yu Wayne (NMN)director:
Sell2026-03-18
Cheng Zhengdirector
Sell2026-03-18

Company Info

Sector

Healthcare

Industry

Medical - Care Facilities

Country

CN

Exchange

Beta

-0.98

Concord Medical Services Holdings Limited, together with its subsidiaries, operates an extensive network of specialized radiotherapy and diagnostic imaging facilities across the People's Republic of China. The company's business activities are structured into two primary divisions: Network and Hospital. Its comprehensive service portfolio includes advanced radiation treatments such as external beam radiotherapy, which utilizes linear accelerators, and precise gamma knife radiosurgery systems designed for both cranial and bodily applications. Additionally, the company provides various diagnostic imaging services, incorporating technologies like computed tomography (CT) scanners. Beyond direct medical treatments, Concord Medical offers essential clinical support services. These encompass assisting healthcare professionals in developing effective treatment protocols, coordinating joint diagnoses among its network doctors, and conducting clinical research. The company also plays a role in human resources, specifically in the recruitment and compensation of its medical and support staff. Furthermore, Concord Medical broadens its services to include the leasing of radiotherapy and diagnostic equipment, providing management expertise, and delivering premium cancer and proton treatment services to other hospitals. Its offerings also extend to teleconsultation, medical information technology solutions, and the sale of medical devices. The company also directly manages and operates specialty cancer hospitals that offer a full range of services, including radiotherapy, diagnostic imaging, chemotherapy, and surgical procedures. As of December 31, 2021, Concord Medical's operational footprint consisted of 16 collaborative centers located within 13 different hospitals. Concord Medical Services Holdings Limited was founded in 1997 and has its corporate headquarters in Beijing, People's Republic of China.